↓ Skip to main content

Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, August 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#19 of 1,132)
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling
Published in
Journal of Experimental & Clinical Cancer Research, August 2018
DOI 10.1186/s13046-018-0844-x
Pubmed ID
Authors

Shijian Xiang, Huoji Chen, Xiaojun Luo, Baichao An, Wenfeng Wu, Siwei Cao, Shifa Ruan, Zhuxian Wang, Lidong Weng, Hongxia Zhu, Qiang Liu

Abstract

Isoliquiritigenin (ISL), a natural flavonoid isolated from the root of licorice (Glycyrrhiza uralensis), has shown various pharmacological properties including anti-oxidant, anti-inflammatory and anti-cancer activities. MicroRNAs (miRNAs), a class of small non-coding RNAs, have been reported as post-transcriptional regulators with altered expression levels in melanoma. This study aims to investigate the anti-melanoma effect of ISL and its potential mechanism. We investigated the effect of ISL on the proliferation and apoptosis of melanoma cell lines with functional assays, such as CCK-8 assay, colony formation assay and flow cytometry. The protein level of apoptosis related genes were measured by western blotting. High-throughput genome sequencing was used for screening differentially expressed miRNAs of melanoma cell lines after the treatment of ISL. We performed functional assays to determine the oncogenic role of miR-301b, the most differentially expressed miRNA, and its target gene leucine rich repeats and immunoglobulin like domains 1 (LRIG1), confirmed by bioinformatic analysis, luciferase reporter assay, western blotting and immunohistochemical assay in melanoma. Immunocompromised mouse models were used to determine the role of miR-301b and its target gene in melanoma tumorigenesis in vivo. The relationship between miR-301b and LRIG1 was further verified in GEO data set and tissue specimens. Functional assays indicated that ISL exerted significant growth inhibition and apoptosis induction on melanoma cells. MiR-301b is the most differentially expressed miRNA after the treatment of ISL and significantly downregulated. The suppressive effect of ISL on cell growth is reversed by ectopic expression of miR-301b. Intratumorally administration of miR-301b angomir enhances the inhibitory effect of ISL on tumor growth in vivo. Bioinformatic analysis showed that miR-301b may target LRIG1, miR-301b suppresses the luciferase activity of reporter constructs containing 3'UTR of LRIG1 as well as the expression level of LRIG1. And the anti-cancer effect of ISL is mitigated when LRIG1 is silenced in vivo and in vitro. Analysis of the melanoma samples obtained from patients shows that LRIG1 is negatively correlated with miR-301b. ISL may inhibit the proliferation of melanoma cells by suppressing miR-301b and inducing its target LRIG1.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 18%
Student > Bachelor 3 11%
Student > Master 3 11%
Unspecified 2 7%
Student > Postgraduate 2 7%
Other 4 14%
Unknown 9 32%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 11%
Medicine and Dentistry 3 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Unspecified 2 7%
Agricultural and Biological Sciences 2 7%
Other 4 14%
Unknown 12 43%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2019.
All research outputs
#1,035,475
of 14,969,286 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#19
of 1,132 outputs
Outputs of similar age
#32,689
of 274,029 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#1
of 1 outputs
Altmetric has tracked 14,969,286 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,132 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,029 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them